[go: up one dir, main page]

SI3256853T1 - Napovedovanje za cepljenje uporabnih epitopov T-celic - Google Patents

Napovedovanje za cepljenje uporabnih epitopov T-celic

Info

Publication number
SI3256853T1
SI3256853T1 SI201631328T SI201631328T SI3256853T1 SI 3256853 T1 SI3256853 T1 SI 3256853T1 SI 201631328 T SI201631328 T SI 201631328T SI 201631328 T SI201631328 T SI 201631328T SI 3256853 T1 SI3256853 T1 SI 3256853T1
Authority
SI
Slovenia
Prior art keywords
vaccination
prediction
useful
cell epitopes
epitopes
Prior art date
Application number
SI201631328T
Other languages
English (en)
Inventor
Ugur Sahin
Martin Lower
Arbel D. Tadmor
Sebastian Boegel
Barbara Schrors
Mathias Vormehr
Sebastian Kreiter
Original Assignee
BioNTech SE
TRON-Translationale Onkologie an der Universitats medizin der Johannes Gutenberg-Universitat Mainz gGmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, TRON-Translationale Onkologie an der Universitats medizin der Johannes Gutenberg-Universitat Mainz gGmbH filed Critical BioNTech SE
Publication of SI3256853T1 publication Critical patent/SI3256853T1/sl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
SI201631328T 2015-02-12 2016-02-09 Napovedovanje za cepljenje uporabnih epitopov T-celic SI3256853T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2015/053021 WO2016128060A1 (en) 2015-02-12 2015-02-12 Predicting t cell epitopes useful for vaccination
PCT/EP2016/052684 WO2016128376A1 (en) 2015-02-12 2016-02-09 Predicting t cell epitopes useful for vaccination
EP16704567.3A EP3256853B1 (en) 2015-02-12 2016-02-09 Predicting t cell epitopes useful for vaccination

Publications (1)

Publication Number Publication Date
SI3256853T1 true SI3256853T1 (sl) 2021-12-31

Family

ID=52469061

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631328T SI3256853T1 (sl) 2015-02-12 2016-02-09 Napovedovanje za cepljenje uporabnih epitopov T-celic

Country Status (21)

Country Link
US (2) US11156617B2 (sl)
EP (2) EP3256853B1 (sl)
JP (2) JP6882178B2 (sl)
KR (3) KR102359213B1 (sl)
CN (2) CN113484523A (sl)
AU (3) AU2016217965B2 (sl)
CA (1) CA2982971A1 (sl)
CY (1) CY1124558T1 (sl)
DK (1) DK3256853T3 (sl)
ES (1) ES2888430T3 (sl)
HR (1) HRP20211419T1 (sl)
HU (1) HUE056658T2 (sl)
IL (1) IL253627B (sl)
LT (1) LT3256853T (sl)
MX (3) MX2017010332A (sl)
PL (1) PL3256853T3 (sl)
PT (1) PT3256853T (sl)
RS (1) RS62416B1 (sl)
SI (1) SI3256853T1 (sl)
SM (1) SMT202100535T1 (sl)
WO (2) WO2016128060A1 (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
CA3008437A1 (en) 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
EP3417289B1 (en) 2016-02-19 2020-12-23 Nant Holdings IP, LLC Methods of immunogenic modulation
KR101925040B1 (ko) * 2016-11-11 2018-12-04 한국과학기술정보연구원 Mhc와 펩타이드 사이의 결합 친화성 예측 방법 및 장치
RU2022106357A (ru) * 2017-02-01 2022-03-24 МОДЕРНАТиЭкс, ИНК. Противораковые рнк-вакцины
KR102565256B1 (ko) 2017-02-12 2023-08-08 바이오엔테크 유에스 인크. Hla 기반 방법 및 조성물, 및 이들의 용도
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
US20210177964A1 (en) * 2017-11-06 2021-06-17 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
CN111836639A (zh) 2018-01-26 2020-10-27 河谷细胞有限公司 用于联合癌症疫苗和免疫辅助疗法的组合物和方法
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
CN112771214B (zh) 2018-09-27 2025-06-13 耐考德治疗股份有限公司 用于选择新表位的方法
EP3881324A1 (en) * 2018-11-15 2021-09-22 Nouscom AG Selection of cancer mutations for generation of a personalized cancer vaccine
US20200224206A1 (en) * 2018-12-05 2020-07-16 Linearx, Inc. Amplicon Expression Vector Vaccines
MX2021007556A (es) * 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
KR102184720B1 (ko) * 2019-10-11 2020-11-30 한국과학기술원 암 세포 표면의 mhc-펩타이드 결합도 예측 방법 및 분석 장치
CN111429965B (zh) * 2020-03-19 2023-04-07 西安交通大学 一种基于多连体特征的t细胞受体对应表位预测方法
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP4182928B1 (en) 2020-07-14 2024-09-04 Myneo Nv Method, system and computer program product for determining presentation likelihoods of neoantigens
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用
CN114984198B (zh) * 2021-02-24 2025-04-29 中国科学院上海药物研究所 包含肿瘤新生抗原纳米制剂和树突状细胞疫苗的试剂盒及其用途
CN113012756A (zh) * 2021-03-08 2021-06-22 杭州纽安津生物科技有限公司 一种个体化肿瘤新生抗原肽的筛选方法及其疫苗制剂
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
DK0900380T3 (da) 1996-04-26 2003-11-03 Seed Capital Investments Fremgangsmåde til udvælgelse og fremstilling af T-celle-peptid-epitoper og vacciner indeholdende disse udvalgte epitoper
ES2305157T3 (es) 1996-09-13 2008-11-01 Lipoxen Technologies Limited Liposomas.
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
AU743066B2 (en) 1997-11-06 2002-01-17 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
AU6289699A (en) 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
ATE418340T1 (de) 1999-05-06 2009-01-15 Univ Wake Forest Zusammensetzungen und methoden zur identifikation von antigenen, die eine immunantwort hervorrufen
JP5640237B2 (ja) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用
CA2394748A1 (en) 1999-12-28 2001-07-05 Epimmune Inc. Optimized minigenes and peptides encoded thereby
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP2333065B1 (en) 2000-01-28 2017-03-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MHC class II restricted T cell epitopes from the cancer antigen NY ESO-1
DE60142615D1 (de) * 2000-04-28 2010-09-02 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
WO2001093902A2 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
DE50214201D1 (de) 2001-06-05 2010-03-25 Curevac Gmbh Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2003245942B2 (en) 2002-06-13 2008-07-24 Merck Patent Gmbh Methods for the identification of all-antigens and their use for cancer therapy and transplantation
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
CN100347191C (zh) 2002-10-02 2007-11-07 霍夫曼-拉罗奇有限公司 新mhcⅱ相关肽
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
PT2286794T (pt) 2003-10-15 2016-07-13 Syncore Biotechnology Co Ltd Uso de lipossomas catiónicos contendo placlitaxel
PT1692516E (pt) 2003-10-24 2011-03-07 Immunaid Pty Ltd Método de terapia
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
EP1838342A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP1715346A1 (en) 2005-04-22 2006-10-25 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method of identifying CD4+ T cell antigens
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
HUE043492T2 (hu) 2005-08-23 2019-08-28 Univ Pennsylvania Módosított nukleozidokat tartalmazó RNS és eljárások az alkalmazására
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
CA2651796A1 (en) 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
WO2008085562A2 (en) 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN103396415B (zh) 2008-03-24 2016-08-10 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
DK2459231T3 (en) 2009-07-31 2016-09-05 Ethris Gmbh RNA with a combination of unmodified and modified nucleotides for protein expression
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
KR102315754B1 (ko) 2010-05-14 2021-10-22 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
EP3431485B2 (en) 2010-10-01 2024-09-04 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
MX360823B (es) 2011-05-24 2018-11-16 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vacunas individualizadas para el cancer.
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
WO2013106496A1 (en) 2012-01-10 2013-07-18 modeRNA Therapeutics Methods and compositions for targeting agents into and across the blood-brain barrier
ES2572606T3 (es) 2012-02-20 2016-06-01 Universita' Degli Studi Di Milano Compuestos miméticos de Smac homo y heterodímeros como inductores de apoptosis
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
CN104662171B (zh) 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
BR122019025681B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US20160022840A1 (en) 2013-03-09 2016-01-28 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20160032316A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
CA2908434C (en) * 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3043826A4 (en) 2013-09-13 2017-05-24 Moderna Therapeutics, Inc. Polynucleotide compositions containing amino acids
WO2015043613A1 (en) 2013-09-26 2015-04-02 Biontech Ag Particles comprising a shell with rna
US20160264614A1 (en) 2013-10-02 2016-09-15 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015117620A1 (en) 2014-02-05 2015-08-13 Biontech Ag A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device
DK4023249T3 (da) 2014-04-23 2025-01-13 Modernatx Inc Nukleinsyrevacciner
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
DK4023755T5 (da) 2014-12-12 2024-07-29 CureVac SE Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse
AU2015373404B2 (en) 2014-12-30 2021-09-09 CureVac SE Artificial nucleic acid molecules
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
WO2017011660A1 (en) * 2015-07-14 2017-01-19 Personal Genome Diagnostics, Inc. Neoantigen analysis
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
WO2018195357A1 (en) 2017-04-19 2018-10-25 Gritstone Oncology, Inc. Neoantigen identification, manufacture, and use
CN110720127A (zh) 2017-06-09 2020-01-21 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
JP7763588B2 (ja) 2017-09-05 2025-11-04 グリットストーン バイオ インコーポレイテッド Ｔ細胞療法用の新生抗原の特定法
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
JP7480064B2 (ja) 2018-02-27 2024-05-09 グリットストーン バイオ インコーポレイテッド パンアレルモデルによる新生抗原の特定方法

Also Published As

Publication number Publication date
JP2021129569A (ja) 2021-09-09
AU2025206387A1 (en) 2025-08-07
CN113484523A (zh) 2021-10-08
JP2018507686A (ja) 2018-03-22
MX2023002858A (es) 2023-04-03
EP3954383A1 (en) 2022-02-16
JP7244571B2 (ja) 2023-03-22
HK1246852A1 (zh) 2018-09-14
KR102670064B1 (ko) 2024-05-29
AU2022215196B2 (en) 2025-04-24
KR102359213B1 (ko) 2022-02-08
JP6882178B2 (ja) 2021-06-02
PT3256853T (pt) 2021-09-16
MX2022000012A (es) 2022-05-20
HRP20211419T1 (hr) 2021-12-10
KR20240095527A (ko) 2024-06-25
ES2888430T3 (es) 2022-01-04
AU2016217965B2 (en) 2022-05-26
KR20220021014A (ko) 2022-02-21
WO2016128376A1 (en) 2016-08-18
US11156617B2 (en) 2021-10-26
US20190250166A1 (en) 2019-08-15
WO2016128060A1 (en) 2016-08-18
CN107430132A (zh) 2017-12-01
RS62416B1 (sr) 2021-10-29
KR20170117514A (ko) 2017-10-23
IL253627A0 (en) 2017-09-28
AU2016217965A1 (en) 2017-08-24
LT3256853T (lt) 2021-10-25
EP3256853B1 (en) 2021-08-18
CY1124558T1 (el) 2022-07-22
CA2982971A1 (en) 2016-08-18
EP3256853A1 (en) 2017-12-20
DK3256853T3 (da) 2021-09-13
MX2017010332A (es) 2018-03-28
SMT202100535T1 (it) 2021-11-12
BR112017017293A2 (pt) 2018-08-28
PL3256853T3 (pl) 2021-12-27
HUE056658T2 (hu) 2022-03-28
CN107430132B (zh) 2021-06-29
IL253627B (en) 2022-04-01
US20220074948A1 (en) 2022-03-10
AU2022215196A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
SI3256853T1 (sl) Napovedovanje za cepljenje uporabnih epitopov T-celic
IL285403A (en) Mhc class i epitope delivering polypeptides
IL261271A (en) Methods for making l-glufosinate
PT3514172T (pt) Imunorrecetores específicos de claudina-6 e epítopos de células t
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3129470T3 (da) Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
PT3114147T (pt) Recetor de antigénio quimérico
DK3140653T3 (da) Direkte immunhistokemianalyse
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
HUE058852T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
PL3325443T3 (pl) Sposób otrzymywania pridopidyny
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
IL248402A0 (en) Humanized antibodies against ceacam1
IL291164A (en) Anti-nme antibody
LT3233813T (lt) Į oksatiaziną panašių junginių gavimo būdai
PL3258674T3 (pl) Wybór procedury ukrywania straty pakietu
DK3132009T3 (da) Fremgangsmåde
DK4268843T3 (da) Forbedrede IL-6-antistoffer
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
HUE045704T2 (hu) Eljárás 5-fluor-1H-pirazolok elõállítására hexafluorpropénbõl kiindulva
HUE049170T2 (hu) Eljárás szubsztituált cikloszerinek elõállítására
LT3178931T (lt) Anti-orai1 antikūnas
LT3126391T (lt) Hpa-1a antikūnai
LT3628731T (lt) Naujas antipresepsino antikūnas